Here's Wouldn't Touch Moderna: Why I Won't Bet on Its Next Growth Engine
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
A concise checklist to verify inputs, validate assumptions, and confirm your zero based budget remains aligned with priorities.
17,617 articlesModerna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
A notable fund sold millions of dollars’ worth of shares as this obesity drug stock jumped on Phase 3 momentum. Here’...
Artificial intelligence is turbocharging drug discovery, cutting years from development timelines and sparking a surg...
A private equity firm just disclosed a sizable stake in Disc Medicine, signaling growing confidence in its red blood ...
A bold policy idea could reshape how the U.S. handles digital assets. This article explains the proposed ARMA bill ai...
A recent FDA decision sparked a powerful rally in Moderna shares, but is the move enough to call it a no-brainer? Thi...
A major partnership reshapes Novo Nordisk's growth trajectory. This deep dive explains what the Vivtex deal means for...
In a candid reflection, ex-disney star hilary duff explains how constant agreement with opportunities can undermine l...
As demand for nickel, copper, cobalt, and manganese grows, TMC faces a pivotal path. This article breaks down two maj...
Qualcomm nudges the industry toward 6G with a bold roadmap. Investors are weighing the potential for faster networks ...
AMD CEO Lisa Su addressed MIT Class of 2026 graduates with a call to apply AI with purpose and judgment, signaling ho...
A new era of obesity and diabetes treatment access could lift Lilly stock. This article breaks down how an oral GLP-1...